Caribou Biosciences (CRBU) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Jun, 2026Executive summary
Annual Meeting of Stockholders scheduled for June 17, 2026, with several key proposals up for vote.
Shareholders are encouraged to vote promptly via internet or telephone for convenience.
Voting matters and shareholder proposals
Election of Andrew Guggenhime, David Johnson, and Nancy Whiting as Class II directors is proposed.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proposal to amend the certificate of incorporation to provide officer exculpation from certain fiduciary duty breaches.
Approval sought for potential adjournment of the meeting if more time is needed for voting or to establish a quorum.
Board of directors and corporate governance
Board recommends voting in favor of all proposals presented at the annual meeting.
Latest events from Caribou Biosciences
- Key CAR-T programs advance toward pivotal trials, with data and regulatory updates due this year.CRBU
Jefferies Global Healthcare Conference 20259 Jul 2026 - Off-the-shelf CAR-T pipeline advances with pivotal trials and autoimmune expansion, backed by strong cash reserves.CRBU
7th Annual Evercore ISI HealthCONx Conference9 Jul 2026 - Upcoming data on allogeneic cell therapies signal progress toward scalable, curative autoimmune treatments.CRBU
Citi's 2024 Global Healthcare Conference8 Jul 2026 - Vispa-cel and CB-011 advance off-the-shelf CAR T therapy with strong efficacy, safety, and access.CRBU
H.C. Wainwright 4th Annual Cell Therapy Virtual Conference30 Jun 2026 - Director elections and auditor ratification passed; officer exculpation amendment failed.CRBU
AGM 202617 Jun 2026 - CB-011 achieved high response rates and durable remissions with manageable safety in r/r myeloma.CRBU
Corporate presentation12 Jun 2026 - Pivotal-ready and phase I CAR T programs advance, with major data updates expected at EHA.CRBU
Jefferies Global Healthcare Conference 20264 Jun 2026 - Allogeneic CAR T programs show strong clinical progress and are advancing toward pivotal trials.CRBU
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Off-the-shelf CAR-T therapies show strong clinical promise and scalable commercial potential.CRBU
Bank of America Global Healthcare Conference 202613 May 2026